(Q38238161)

31 August 2017

title

Optimizing dosing of oncology drugs (English)

1 reference

31 August 2017

L Minasian

1

1 reference

31 August 2017

O Rosen

2

1 reference

31 August 2017

D Auclair

3

1 reference

31 August 2017

A Rahman

4

1 reference

31 August 2017

R Pazdur

5

1 reference

31 August 2017

R L Schilsky

6

1 reference

31 August 2017

language of work or name

English

0 references

publication date

8 August 2014

1 reference

Clinical Pharmacology & Therapeutics

31 August 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

31 August 2017

volume

96

1 reference

31 August 2017

issue

5

1 reference

31 August 2017

page(s)

572-579

1 reference

Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.153

Dose escalation methods in phase I cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.153

Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.153

Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.153

Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.153

How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.153

Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.153

U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.153

Toward patient-centered drug development in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.153

Reducing the toxicity of cancer therapy: recognizing needs, taking action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.153

Accelerated approval of oncology products: the food and drug administration experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.153

Oversight of Fast-Track Drug Approval by FDA Stuck in Low Gear, Critics Say

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.153

The Food and Drug Administration Amendments Act and postmarketing commitments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.153

Maximum-tolerated dose, optimum biologic dose, or optimum clinical value: dosing determination of cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.153

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2014.153

1 reference

31 August 2017

1 reference